Clinical Trials Sponsored by Xilio Development, Inc.

Total 1133 results

Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder

United States
Ironshore Pharmaceuticals and Development, Inc

Completed

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD (CEES)

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)

Multidrug Resistant Tuberculosis

Philippines, South Africa
Otsuka Pharmaceutical Development & Commercialization...

Completed

Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant

Belgium, Germany, Italy, Spain, Sweden, United States, Canada, Australia, Netherlands, Czechia, Poland, Denmark, Israel, Hungary, Russian Federation, South Africa, United Kingdom, Romania, Argentina, Norway
Otsuka Pharmaceutical Development & Commercialization...

Terminated

A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

Schizophrenia | Major Depressive Disorder | Bipolar 1 Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (NOCTURNE)

Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole

Nervous System Diseases | Schizophrenia | Mental Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Chronic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease

Australia, Belgium, Italy, Spain, Sweden, United States, Canada, Netherlands, Czechia, Poland, Germany, Russian Federation, Hungary, Israel, Puerto Rico, Argentina, Denmark, South Africa, United Kingdom, Norway, France, Romania
Otsuka Pharmaceutical Development & Commercialization...

Completed

Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) (OSMITTER)

Device Latency

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Poland, Serbia, Russian Federation, Germany, Canada, France
Otsuka Pharmaceutical Development & Commercialization...

Completed

Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis

Pediatric | Multidrug Resistant Tuberculosis

Philippines, South Africa
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features. (ATTAIN 267)

Adolescent Schizophrenia | Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features

India, United States, Bulgaria, Croatia, Hungary, Malaysia, Philippines, Poland, Romania, Russian Federation, Serbia, Taiwan, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia (STEP 203)

Schizophrenia

United States, Croatia, Serbia, Bulgaria, India, Korea, Republic of, Philippines, Romania, Russian Federation, Slovakia, Taiwan, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization...

Withdrawn

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

Nervous System Diseases | Schizophrenia | Mental Disorder | Bipolar 1 Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia (ATTAIN 266)

Schizophrenia

United States, India, Malaysia, Philippines, Romania, Russian Federation, Taiwan
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia (SALACIA)

Hyponatremia | Inappropriate ADH Syndrome | Dilutional Hyponatremia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer

Advanced Cancer

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder

Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Aripiprazole in Children and Adolescents With Bipolar I Disorder

Bipolar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

Ulcerative Colitis

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

Congestive Heart Failure

United States, Canada, Netherlands, United Kingdom, France, Spain, Germany, Switzerland, Italy, Brazil, Argentina, Russian Federation, Belgium, Romania, Czech Republic, Norway, Poland, Sweden
Otsuka Pharmaceutical Development & Commercialization...

Completed

Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents

Schizophrenia | Mania
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder (JUNIPER)

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney Disease (ARPKD)

United States, Belgium, Spain, Germany, United Kingdom, Poland
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

United States, Spain, Hungary, Italy, Canada, Czechia, South Africa, Poland, Bulgaria, France
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary, Poland, Puerto Rico
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD

Post Traumatic Stress Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment

Smoking Cessation

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Germany, Italy, Belgium, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

Borderline Personality Disorder

United States, Spain, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects

Drug-drug Interaction

Australia
Ironshore Pharmaceuticals and Development, Inc

Completed

Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

Attention-Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

Adult Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) (OSMITTER)

Device Latency

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder

Adult ADHD

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

Tourette's Disorder

Germany, United States, Bulgaria, Romania, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Tourette's Disorder

United States, Taiwan, Korea, Republic of, Mexico, Canada, Hungary
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Tourette's Disorder

United States, Germany, Taiwan, Korea, Republic of, Mexico, Hungary, Bulgaria, Ukraine, Romania, Canada

Clinical Trials Sponsored by Xilio Development, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations